Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease.
Neurology
; 66(4): 602-4, 2006 Feb 28.
Article
em En
| MEDLINE
| ID: mdl-16505324
ABSTRACT
LY450139 dihydrate, a gamma-secretase inhibitor, was studied in a randomized, controlled trial of 70 patients with Alzheimer disease. Subjects were given 30 mg for 1 week followed by 40 mg for 5 weeks. Treatment was well tolerated. Abeta(1-40) in plasma decreased by 38.2%; in CSF, Abeta(1-40) decreased by 4.42 +/- 9.55% (p = not significant). Higher drug doses may result in additional decreases in plasma Abeta concentrations and a measurable decrease in CSF Abeta.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Endopeptidases
/
Azepinas
/
Alanina
/
Doença de Alzheimer
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article